Highlighting results from first FDA-reported study for treatment of presbyopia
September 27th 2021George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Autoantibodies in severe COVID-19: Possible culprits in long-term COVID-19 cases
September 24th 2021Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.
Glaukos unveils licensing agreement for compounds that target Demodex mites
September 20th 2021Glaukos has entered into a licensing agreement with Attillaps Holdings Inc., giving it an exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites.
Considering keratoconus-like changes after DMEK in Fuchs' dystrophy
September 20th 2021A retrospective review was performed to describe changes in corneal thickness and to identify the incidence of posterior corneal changes characteristic of keratoconus, following DMEK surgery. Here’s what investigators found.